Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by PepGen, Inc

PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
From PepGen, Inc
Via GlobeNewswire
Tickers PEPG
PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
From PepGen, Inc
Via GlobeNewswire
Tickers PEPG
PepGen to Participate in the Stifel 2022 Healthcare Conference
From PepGen, Inc
Via GlobeNewswire
Tickers PEPG
PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress
From PepGen, Inc
Via GlobeNewswire
Tickers PEPG
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen, Inc
Via GlobeNewswire
Tickers PEPG
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.